Patent Exhaustion Doctrine In Poland.
1. Legal Framework in Poland
Under Polish law, patent exhaustion is regional (EEA-wide), not purely national.
Key Rule:
A patent holder cannot prevent further distribution of a patented product if:
- The product has been lawfully placed on the market, and
- This occurred within the European Economic Area (EEA),
- By the patent holder or with their consent.
However:
The patent holder retains rights if:
- The product was first sold outside the EEA (no international exhaustion), or
- The condition of the product has been changed or impaired after sale.
2. EU Influence on Polish Doctrine
Poland follows EU jurisprudence, especially rulings of the Court of Justice of the European Union, which strongly shapes how exhaustion is interpreted.
3. Detailed Case Laws
Below are more than five important cases, including EU and Polish-relevant decisions, explained in depth.
Case 1: Centrafarm BV v Sterling Drug Inc
Facts:
Sterling Drug held patent rights for pharmaceuticals in different EU states. Centrafarm imported patented drugs from a lower-price country and resold them in a higher-price country.
Issue:
Can a patent holder block parallel imports within the EU?
Judgment:
The CJEU held:
- Once a patented product is sold in one Member State with consent,
- The patent holder cannot use national patent rights to stop resale in another Member State.
Principle Established:
- Regional (EU) exhaustion doctrine
- Patent rights cannot be used to partition markets within the EU.
Importance for Poland:
This is foundational—Poland, as an EU member, applies this rule directly.
Case 2: Merck & Co. Inc v Stephar BV and Exler
Facts:
Merck sold a drug in Italy (where no patent protection existed at the time) and later tried to prevent its import into countries where it held patents.
Issue:
Does exhaustion apply if the product was sold in a country without patent protection?
Judgment:
Yes. The Court ruled:
- If the patent holder voluntarily markets the product in a Member State,
- They accept the consequences, including parallel trade.
Principle:
- Exhaustion applies even if the first sale occurred in a country without patent protection.
Relevance:
This prevents strategic exploitation of legal differences across EU states.
Case 3: Silhouette International Schmied GmbH v Hartlauer Handelsgesellschaft mbH
Facts:
Silhouette sold goods outside the EU and tried to prevent their import into the EU.
Issue:
Does the EU recognize international exhaustion?
Judgment:
No. The Court ruled:
- Exhaustion applies only within the EEA, not globally.
Principle:
- No international exhaustion in EU law
Importance for Poland:
Poland strictly follows this:
- Goods first sold outside the EEA can be blocked from import.
Case 4: Zino Davidoff SA v A & G Imports Ltd
Facts:
Davidoff products were sold outside the EEA and imported without explicit consent.
Issue:
What constitutes “consent” to market goods in the EEA?
Judgment:
- Consent must be explicit and unequivocal.
- It cannot be presumed.
Principle:
- Strong protection for patent holders against unauthorized imports.
Relevance:
Polish courts apply strict standards for proving consent.
Case 5: Bristol-Myers Squibb v Paranova
Facts:
Parallel importers repackaged pharmaceutical products and resold them.
Issue:
Can patent holders oppose resale if products are modified?
Judgment:
Repackaging is allowed only if:
- It is necessary to market the product,
- It does not harm the product’s condition,
- The original manufacturer’s reputation is not damaged.
Principle:
- Exhaustion is limited when product integrity is affected.
Importance:
Highly relevant in Poland’s pharmaceutical sector.
Case 6: Boehringer Ingelheim v Swingward Ltd
Facts:
Further clarification on repackaging and relabeling of drugs.
Judgment:
- The importer must notify the patent holder before resale.
- Packaging must clearly identify the party responsible.
Principle:
- Transparency obligations in parallel imports.
Relevance:
Applied in Poland for regulating pharmaceutical distribution.
Case 7: Polish Supreme Court Case (Parallel Imports of Pharmaceuticals)
Entity:
Polish Supreme Court
Facts:
A distributor imported pharmaceuticals from another EEA country and resold them in Poland.
Issue:
Whether the patent holder could block resale based on national rights.
Judgment:
- The Court upheld EU exhaustion principles.
- Once marketed in the EEA, Polish patent rights are exhausted.
Principle:
- Full alignment with EU internal market rules.
Case 8: Polish Administrative Court on Trademark/Patent Overlap
Entity:
Supreme Administrative Court of Poland
Facts:
Case involving both patent and trademark rights in imported goods.
Issue:
Can IP rights be used to block lawful parallel imports?
Judgment:
- IP rights cannot be used abusively to restrict trade.
- Exhaustion applies unless legitimate reasons exist (e.g., product alteration).
Principle:
- Anti-abuse doctrine in IP enforcement.
4. Key Principles Derived
From these cases, the Polish doctrine includes:
1. Regional Exhaustion (EEA-wide)
- Rights are exhausted only after EEA first sale
2. No International Exhaustion
- Imports from outside EEA can be blocked
3. Consent Requirement
- Must be clear and explicit
4. Product Integrity Exception
- Rights revive if goods are altered or damaged
5. Free Movement of Goods
- Patent law cannot restrict intra-EU trade
5. Practical Example
If a patented drug is:
- Sold in Germany → Can be resold in Poland freely
- Sold in India → Import into Poland can be blocked
6. Conclusion
The Patent Exhaustion Doctrine in Poland is deeply harmonized with EU law, prioritizing:
- Market integration
- Consumer access
- Prevention of artificial trade barriers
At the same time, it protects patent holders through:
- Strict consent rules
- Safeguards against product alteration
- Territorial limits (EEA-only exhaustion)
RELATED Blog
comments